# of Displayed Technologies: 10 / 53


Software for Data-Driven Detection of Space-Time Profiles of Events Detected on the EEG Manifold
TS-004706 — Based on delayed co-detection, this software detects space-time profiles through a data-driven approach.
  • College:
  • Inventors: Malerba, Paola; Snedden, Ali
  • Licensing Officer: Murrah, Kyle

Inhibition of Purinergic Signaling to Promote Neotissue Formation and Prevent Pathological Remodeling in Tissue Engineered Vascular Conduits, Patches, and Valves.
TS-004524 — In engineered cardiovascular tissues, inhibiting purinergic signaling will promote high-quality neo tissue formation and prevent pathological remodeling. Inhibiting the P2Y12 receptor sustains a multitude of other necessary functions but prevents a detrimental excess.
To promote high quality neo tissue formation and inhibit pathological remodeling within engineered cardiovascular tissues, purinergic signaling must be inhibited. The P2Y12 receptor inhibitor called prasugrel, or Effient®, reduces the rate of thrombotic cardiovascular (CV) events (including sten…
  • College:
  • Inventors: Breuer, Christopher; Reinhardt, James; Turner, Mackenzie
  • Licensing Officer: Murrah, Kyle

Lip Guard/Retractor Device
TS-004523 — The LabraGuard lip retractor device intends to prevent injury during oral surgery. The unique design allows independent functioning of each segment for improved patient outcomes.
The LabraGuard is designed to prevent oral injuries by retracting the lips during procedures such as a tonsillectomy, transoral surgery or adenoidectomy. Two narrow connecting pieces fit into each of the three parts of the guard, which allows each segment to function independently. This prevents any…
  • College:
  • Inventors: Jatana, Kris; Elmaraghy, Charles
  • Licensing Officer: Murrah, Kyle

Software Assisted Morbidity & Mortality (M&M) Conferencing
TS-002702 — Patient safety is always a priority for any healthcare setting. Researchers at Nationwide Children’s Hospital developed the Software Assisted Morbidity and Mortality Conferencing platform that was adopted from a previous paper-managed process. The web-application improves patient safety throug…
  • College:
  • Inventors: Hampl, Josh; Besner, Gail; Kenney, Brian; Murnane, Jami
  • Licensing Officer: Murrah, Kyle

ACTIVE-mini 2.0 (BabySure)
TS-002384 — Movement disorders in the United States are often diagnosed after the infant stage. However, early detection and intervention can result in better outcomes. Physical therapists and researchers at Nationwide Children’s Hospital developed the BabySure which detects abnormal movements early on. The device uses color tracking and a depth camera system to track movements in a 2-minute video, which is then compiled to generate a Motor Function Score to compare to typical age-matched peers for early identification or to monitor movement changes in children with known movement impairments.
  • College:
  • Inventors: Lowes, Linda; Alfano, Lindsay
  • Licensing Officer: Murrah, Kyle

Understanding the Clinical Care Practices in LGMD: Patient-Facing Survey
TS-002380 — Limb-girdle muscular dystrophy (LGMD) is a group of disorders that causes weakness in the arms and legs with proximal muscles being the most affected. Currently, there is no standard of care established for LGMD. Physical therapist and researcher, Lindsay Alfano, PT, DPT, PCS, at Nationwide Children’s Hospital’s Center for Gene Therapy created a survey to further understand current diagnosis and patient care practices for LGMD. The survey is designed for families, patients, caregivers, and individuals to gauge the patient’s background and LGMD history (first diagnosis, more frequently seen healthcare providers, testing done, use of assistive devices, access to therapy, etc.). By understanding LGMD patient care through the patient’s perspective, the survey moves the healthcare field one step closer to establishing the best practices of care for LGMD.
  • College:
  • Inventors: Alfano, Lindsay
  • Licensing Officer: Murrah, Kyle

Quantifying Skeletal Muscle Perfusion Using Dynamic PET Imaging of Fluorine-18-Labeled Radionuclides
TS-002316 — Musculoskeletal conditions affect 1.71 billion people worldwide. Researchers at Nationwide Children’s Hospitals developed a novel dynamic approach of PET imaging using commercially available fluorine-18-labeled radionuclides to quantify absolute measures of skeletal muscle perfusion. By utilizing 18F-labled radionuclides instead of cyclotron production of oxygen-15 water, the methodology is widely accessible to any healthcare system possessing a PET camera by lowering the costs and limiting the need of highly trained radiopharamcy teams to produce and administer oxygen-15 water. Additionally, the methodology will quantify skeletal muscle perfusion for a wide range of muscoskeletal applications and quantify abnormalties from muscle astrophy: any vascular or muscoskeletal disease resulting from underlying ischemia to muscle, ischemic vascular disease, spinal muscular disease, Charcot-Marie-Tooth, etc.
  • College:
  • Inventors: Stacy, Mitchel; Chou, Ting-Heng
  • Licensing Officer: Murrah, Kyle

HEK293 - MIB1-FLAG & HEK293 - HA-Ubiquitin
TS-002315 — The standard human embryonic kidney 293 (HEK293) cell line is widely used in cancer research, vaccine production, adenovirus and adeno-associated viral vectors and gene therapy. Researchers at Nationwide Children’s Hospital have discovered a new use for the HEK293 cell line: generating stable HEK293 cells expressing MiB1-FLAG and hemagglutinin (HA)–ubiquitin. MiB1-FLAG plays a vital role in cell migration and ubiquitin marks HA for degradation and affects its activity. As a result, the HEK293 cells establish a proper immune response, wound repair and tissue homeostasis while attacking hemagglutinin?????
  • College:
  • Inventors: Garg, Vidu; Majumdar, Uddalak
  • Licensing Officer: Murrah, Kyle

Development of AAV gene therapy for eIF2B5 related vanishing white matter disease
TS-002177 — Researchers at Nationwide Children's Hospital are in the process of developing an Adeno-Associated Virus (AAV) gene therapy for the Eukaryotic Initiation Factor 2B complex (EIF2B5) related Vanishing White Matter Disease (VWM), an inherited pediatric leukodystrophy disease resulting from autosomal recessive mutations in the five subunit genes of EIF2B5. VWM deteriorates the central nervous system’s white matter which affects the brain’s communication and function. Common symptoms include spasticity, ataxia, hypotonia, speech issues, dysphagia, vision and hearing impairments along with cognitive deficits. The research team is evaluating the CSF delivery of AAV serotype 9 that will target astrocytes which are central in VWM pathology in order to constitute potential therapeutic targets. The AAV vectors will provide wildtype copies of EIF2B5 to address the loss of function resultant from mutations.
  • College:
  • Inventors: Bradbury, Allison; Flanigan, Kevin
  • Licensing Officer: Murrah, Kyle

Methods for Anticipating Antibiotic Sensitivity in Bacteria Released from Biofilm Residence
TS-002176 — In order to effectively treat bacterial infections, a clear understanding of the bacterium’s antibiotic sensitivity is needed. Researchers at Nationwide Children’s Hospital’s Center for Microbial Pathogenesis created a new method to assist in prescribing antibiotics for infections caused by a biofilm to reduce the dosage and the length of antibiotic treatments.
Depending on the bacteria’s physiologic state the antibiotic sensitivity can be highly variable. Originally, bacteria were believed to exist in two physiologic states: planktonic and biofilm. However, the research team based their methods on two additional but transient physiologic states they…
  • College:
  • Inventors: Bakaletz, Lauren; Goodman, Steven
  • Licensing Officer: Murrah, Kyle

Show More Technologies

Loading icon